🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 17/02/2023 | 291,24 | 295,69 | 290,00 | 293,66 | +0,55% | 1,95% | 1.278.000 |
| 16/02/2023 | 296,17 | 298,39 | 291,49 | 292,04 | -2,25% | 2,33% | 1.039.300 |
| 15/02/2023 | 299,06 | 299,57 | 294,08 | 298,75 | -0,50% | 1,84% | 899.800 |
| 14/02/2023 | 297,47 | 301,35 | 295,00 | 300,25 | +0,36% | 2,13% | 1.190.400 |
| 13/02/2023 | 295,53 | 300,99 | 295,53 | 299,18 | +0,60% | 1,85% | 1.053.300 |
| 10/02/2023 | 291,95 | 298,49 | 290,17 | 297,40 | +1,99% | 2,85% | 1.342.100 |
| 09/02/2023 | 293,10 | 295,52 | 289,58 | 291,60 | -0,59% | 2,03% | 1.798.700 |
| 08/02/2023 | 302,98 | 303,11 | 293,09 | 293,33 | -4,93% | 3,31% | 2.168.600 |
| 07/02/2023 | 303,59 | 309,44 | 302,24 | 308,54 | +1,20% | 2,37% | 1.300.600 |
| 06/02/2023 | 299,81 | 310,28 | 299,72 | 304,87 | +1,28% | 3,52% | 1.295.600 |
| 03/02/2023 | 304,56 | 306,40 | 300,75 | 301,02 | -0,91% | 1,86% | 1.621.300 |
| 02/02/2023 | 315,00 | 315,77 | 301,06 | 303,78 | -4,25% | 4,67% | 1.944.000 |
| 01/02/2023 | 321,50 | 323,10 | 312,58 | 317,27 | -1,80% | 3,27% | 1.237.700 |
| 31/01/2023 | 319,98 | 325,19 | 319,98 | 323,10 | +0,98% | 1,63% | 1.352.900 |
| 30/01/2023 | 321,21 | 322,69 | 319,23 | 319,98 | -0,46% | 1,08% | 2.261.800 |
| 27/01/2023 | 321,00 | 323,67 | 319,58 | 321,45 | +0,13% | 1,27% | 1.288.600 |
| 26/01/2023 | 315,75 | 321,11 | 314,60 | 321,02 | +1,82% | 2,06% | 1.302.000 |
| 25/01/2023 | 314,36 | 315,33 | 312,00 | 315,28 | +0,55% | 1,06% | 1.315.100 |
| 24/01/2023 | 311,80 | 313,89 | 309,53 | 313,57 | +0,56% | 1,40% | 932.300 |
| 23/01/2023 | 309,59 | 312,43 | 308,53 | 311,81 | +0,64% | 1,26% | 1.810.700 |
| 20/01/2023 | 306,31 | 310,46 | 305,49 | 309,84 | +0,62% | 1,62% | 1.466.200 |
| 19/01/2023 | 310,03 | 311,54 | 302,52 | 307,94 | -0,62% | 2,91% | 1.551.500 |
| 18/01/2023 | 311,80 | 312,66 | 307,06 | 309,86 | -0,68% | 1,80% | 2.264.900 |
| 17/01/2023 | 303,49 | 312,35 | 302,62 | 311,98 | +3,67% | 3,21% | 2.070.700 |
| 13/01/2023 | 296,39 | 301,26 | 295,58 | 300,94 | +1,58% | 1,92% | 1.448.300 |
| 12/01/2023 | 290,22 | 296,28 | 288,72 | 296,25 | +1,37% | 2,60% | 1.801.100 |
| 11/01/2023 | 289,87 | 292,89 | 286,89 | 292,25 | +1,21% | 2,07% | 1.630.300 |
| 10/01/2023 | 283,23 | 288,85 | 282,58 | 288,75 | +1,95% | 2,21% | 1.038.900 |
| 09/01/2023 | 290,09 | 291,66 | 282,21 | 283,23 | -2,41% | 3,26% | 1.299.200 |
| 06/01/2023 | 291,81 | 293,65 | 288,62 | 290,21 | +0,81% | 1,72% | 943.400 |